

Efficacy and Safety of Combined PD-I Inhibitor with Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis [Corrigendum]

Chen K, Huang X, Chen J, Zhang S. *Onco Targets Ther.* 2025;18:283–296.

The authors have advised that [Table 1](#) on page 287 is incorrect. The Characteristics “Sintilimab” and “Toripalimab” listed in the PD-1 inhibitors section are interchanged.

The correct [Table 1](#) is as follows.

Table 1 Baseline characteristics of patients

Characteristics	n (%) (N=103)
Age (year), mean (SD)	51.00 (41.00, 58.00)
Gender	
Male	75 (72.82)
Female	28 (27.18)
Ethnic	
Han Chinese	98 (95.1)
Other	5 (4.9)
Clinical stage (cases)	
III	42 (40.78)
IVA	61 (59.22)
TNM stage - T stage (cases)	
I	2 (1.94)
2	14 (13.59)
3	54 (52.43)
4	33 (32.04)
TNM stage - N stage (cases)	
0	7 (6.80)
I	15 (14.56)
2	46 (44.66)
3	35 (33.98)
History of smoking	
Nonsmoker	56 (54.4)
Former smoker	6 (5.8)
Current smoker	41 (39.9)
Alcohol consumption	
Nondrinker	72 (69.9)
Former drinker	6 (5.8)
Current drinker	25 (24.2)
EBV DNA (IU/mL), median (IQR)	400.00 (400.00, 2140.00)
Neutrophil-to-lymphocyte ratio	
≤3.5	100 (97.1)
>3.5	3 (2.9)

(Continued)

Table 1 (Continued).

Characteristics	n (%) (N=103)
Therapy received	
TP (nab-paclitaxel)	61 (59.22%)
DP (docetaxel)	38 (36.89%)
GP (cisplatin + gemcitabine)	4 (3.88%)
PD-I inhibitors	
Serplulimab	39 (37.86%)
Toripalimab	37 (35.92%)
Sintilimab	27 (26.21%)

Abbreviation: n, number of cases; SD, standard deviation; TNM stage, Tumor-Node-Metastasis stage; EBV DNA, Epstein-Barr Virus Deoxyribonucleic Acid; IU/mL, International Units per milliliter; IQR, Interquartile Range; PD-I inhibitors, Programmed Cell Death Protein I Inhibitors.

The authors apologize for the error.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

Dovepress
Taylor & Francis Group